Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
iPreg is a Taiwan-based reproductive medicine company developing and commercializing microfluidic sperm sorting devices and related fertility technologies. Its core offering is the SperŜort platform, which uses biomimetic microfluidic methods to select highly motile, morphologically normal sperm with improved DNA integrity for use in assisted reproduction procedures such as IVF and ICSI. The company also markets adjacent products including the SperŜort Hatcher and SperŜort Station, and has introduced an AI-enabled consulting and sperm-analysis offering for fertility centers. iPreg appears to operate as a medical device and fertility technology company rather than a therapeutics developer, with a focus on improving sperm selection workflows and reproductive outcomes in infertility care.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on iPreg.